Literature DB >> 26824941

Toward an Evidence-Based Nonclinical Road Map for Evaluating the Efficacy of New Tuberculosis (TB) Drug Regimens: Proceedings of a Critical Path to TB Drug Regimens-National Institute of Allergy and Infectious Diseases In Vivo Pharmacology Workshop for TB Drug Development.

Eric Nuermberger1, Christine Sizemore2, Klaus Romero3, Debra Hanna4.   

Abstract

Novel tuberculosis (TB) drug regimens are urgently needed, and their development will be enabled by improved preclinical approaches that more effectively inform and ensure safe selection of clinical candidates and drug combination/regimens. An evidence-based approach for the assessment of nonclinical models supporting TB drug development has been proposed by a joint partnership between the National Institute of Allergy and Infectious Diseases (NIAID) and the Critical Path to TB Drug Regimens (CPTR) Consortium.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26824941      PMCID： PMC4775974          DOI： 10.1128/AAC.02041-15

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  15 in total

Review 1.  Pharmacokinetic-pharmacodynamic and dose-response relationships of antituberculosis drugs: recommendations and standards for industry and academia.

Authors:  Tawanda Gumbo; Iñigo Angulo-Barturen; Santiago Ferrer-Bazaga
Journal:  J Infect Dis       Date:  2015-06-15       Impact factor: 5.226

2.  Evaluation of a mouse model of necrotic granuloma formation using C3HeB/FeJ mice for testing of drugs against Mycobacterium tuberculosis.

Authors:  Emily R Driver; Gavin J Ryan; Donald R Hoff; Scott M Irwin; Randall J Basaraba; Igor Kramnik; Anne J Lenaerts
Journal:  Antimicrob Agents Chemother       Date:  2012-04-02       Impact factor: 5.191

3.  Comparison of the 'Denver regimen' against acute tuberculosis in the mouse and guinea pig.

Authors:  Zahoor Ahmad; Eric L Nuermberger; Rokeya Tasneen; Michael L Pinn; Kathy N Williams; Charles A Peloquin; Jacques H Grosset; Petros C Karakousis
Journal:  J Antimicrob Chemother       Date:  2010-01-31       Impact factor: 5.790

4.  The combination of rifampin plus moxifloxacin is synergistic for suppression of resistance but antagonistic for cell kill of Mycobacterium tuberculosis as determined in a hollow-fiber infection model.

Authors:  G L Drusano; Nicole Sgambati; Adam Eichas; David L Brown; Robert Kulawy; Arnold Louie
Journal:  MBio       Date:  2010-08-10       Impact factor: 7.867

5.  Forecasting Accuracy of the Hollow Fiber Model of Tuberculosis for Clinical Therapeutic Outcomes.

Authors:  Tawanda Gumbo; Jotam G Pasipanodya; Klaus Romero; Debra Hanna; Eric Nuermberger
Journal:  Clin Infect Dis       Date:  2015-08-15       Impact factor: 9.079

6.  Correlations Between the Hollow Fiber Model of Tuberculosis and Therapeutic Events in Tuberculosis Patients: Learn and Confirm.

Authors:  Tawanda Gumbo; Jotam G Pasipanodya; Eric Nuermberger; Klaus Romero; Debra Hanna
Journal:  Clin Infect Dis       Date:  2015-08-15       Impact factor: 9.079

7.  Resuscitation-promoting factors reveal an occult population of tubercle Bacilli in Sputum.

Authors:  Galina V Mukamolova; Obolbek Turapov; Joanne Malkin; Gerrit Woltmann; Michael R Barer
Journal:  Am J Respir Crit Care Med       Date:  2009-10-29       Impact factor: 21.405

8.  A new in vivo model to test anti-tuberculosis drugs using fluorescence imaging.

Authors:  Andrea Zelmer; Paul Carroll; Nuria Andreu; Kristine Hagens; Jacqueline Mahlo; Natalja Redinger; Brian D Robertson; Siouxsie Wiles; Theresa H Ward; Tanya Parish; Jorge Ripoll; Gregory J Bancroft; Ulrich E Schaible
Journal:  J Antimicrob Chemother       Date:  2012-05-25       Impact factor: 5.790

9.  Heterogeneous disease progression and treatment response in a C3HeB/FeJ mouse model of tuberculosis.

Authors:  Jean-Philippe Lanoix; Anne J Lenaerts; Eric L Nuermberger
Journal:  Dis Model Mech       Date:  2015-03-30       Impact factor: 5.758

10.  Preclinical Evaluations To Identify Optimal Linezolid Regimens for Tuberculosis Therapy.

Authors:  Ashley N Brown; George L Drusano; Jonathan R Adams; Jaime L Rodriquez; Kalyani Jambunathan; Dodge L Baluya; David L Brown; Awewura Kwara; Jon C Mirsalis; Richard Hafner; Arnold Louie
Journal:  MBio       Date:  2015-11-03       Impact factor: 7.867
View more
  10 in total

1.  Assessment of Bactericidal Drug Activity and Treatment Outcome in a Mouse Tuberculosis Model Using a Clinical Beijing Strain.

Authors:  Bas C Mourik; Gerjo J de Knegt; Annelies Verbon; Johan W Mouton; Hannelore I Bax; Jurriaan E M de Steenwinkel
Journal:  Antimicrob Agents Chemother       Date:  2017-09-22       Impact factor: 5.191

2.  Accelerating Biomedical Discoveries through Rigor and Transparency.

Authors:  Judith A Hewitt; Liliana L Brown; Stephanie J Murphy; Franziska Grieder; Shai D Silberberg
Journal:  ILAR J       Date:  2017-07-01

3.  Long-acting formulations for the treatment of latent tuberculous infection: opportunities and challenges.

Authors:  S Swindells; M Siccardi; S E Barrett; D B Olsen; J A Grobler; A T Podany; E Nuermberger; P Kim; C E Barry; A Owen; D Hazuda; C Flexner
Journal:  Int J Tuberc Lung Dis       Date:  2018-02-01       Impact factor: 2.373

Review 4.  Drug permeation and metabolism in Mycobacterium tuberculosis: Prioritising local exposure as essential criterion in new TB drug development.

Authors:  Lloyd Tanner; Paolo Denti; Lubbe Wiesner; Digby F Warner
Journal:  IUBMB Life       Date:  2018-06-22       Impact factor: 3.885

5.  Driving the Way to Tuberculosis Elimination: The Essential Role of Fundamental Research.

Authors:  Christian Lienhardt; Alison M Kraigsley; Christine F Sizemore
Journal:  Clin Infect Dis       Date:  2016-06-05       Impact factor: 9.079

Review 6.  Advancing the development of new tuberculosis treatment regimens: The essential role of translational and clinical pharmacology and microbiology.

Authors:  Kelly E Dooley; Debra Hanna; Vidya Mave; Kathleen Eisenach; Radojka M Savic
Journal:  PLoS Med       Date:  2019-07-05       Impact factor: 11.069

Review 7.  Model-Informed Drug Development for Anti-Infectives: State of the Art and Future.

Authors:  Craig R Rayner; Patrick F Smith; David Andes; Kayla Andrews; Hartmut Derendorf; Lena E Friberg; Debra Hanna; Alex Lepak; Edward Mills; Thomas M Polasek; Jason A Roberts; Virna Schuck; Mark J Shelton; David Wesche; Karen Rowland-Yeo
Journal:  Clin Pharmacol Ther       Date:  2021-03-09       Impact factor: 6.875

8.  Chemical-genetic interaction mapping links carbon metabolism and cell wall structure to tuberculosis drug efficacy.

Authors:  Eun-Ik Koh; Peter O Oluoch; Nadine Ruecker; Megan K Proulx; Vijay Soni; Kenan C Murphy; Kadamba Papavinasasundaram; Charlotte J Reames; Carolina Trujillo; Anisha Zaveri; Matthew D Zimmerman; Roshanak Aslebagh; Richard E Baker; Scott A Shaffer; Kristine M Guinn; Michael Fitzgerald; Véronique Dartois; Sabine Ehrt; Deborah T Hung; Thomas R Ioerger; Eric J Rubin; Kyu Y Rhee; Dirk Schnappinger; Christopher M Sassetti
Journal:  Proc Natl Acad Sci U S A       Date:  2022-04-05       Impact factor: 12.779

9.  Improving treatment outcome assessment in a mouse tuberculosis model.

Authors:  Bas C Mourik; Robin J Svensson; Gerjo J de Knegt; Hannelore I Bax; Annelies Verbon; Ulrika S H Simonsson; Jurriaan E M de Steenwinkel
Journal:  Sci Rep       Date:  2018-04-09       Impact factor: 4.379

10.  OPC-167832, a Novel Carbostyril Derivative with Potent Antituberculosis Activity as a DprE1 Inhibitor.

Authors:  Norimitsu Hariguchi; Xiuhao Chen; Yohei Hayashi; Yoshikazu Kawano; Mamoru Fujiwara; Miki Matsuba; Hiroshi Shimizu; Yoshio Ohba; Izuru Nakamura; Ryuki Kitamoto; Toshio Shinohara; Yukitaka Uematsu; Shunpei Ishikawa; Motohiro Itotani; Yoshikazu Haraguchi; Isao Takemura; Makoto Matsumoto
Journal:  Antimicrob Agents Chemother       Date:  2020-05-21       Impact factor: 5.191
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.